Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in the Western countries. The entire pathogenesis of CLL is not clear now, but defective regulation of apoptosis seems to be more important than uncontrolled cell proliferation in CLL. There are two main pathways of apoptosis: the extrinsic pathway and the intrinsic pathway. It is worth noting that the intrinsic pathway, rather than the extrinsic pathway, appears to be the key mediator of impaired apoptosis in CLL as a result of B-cell lymphoma 2 (Bcl-2) upregulation. One subclass of pro-apoptotic members within the Bcl-2 family are Bcl-2 homology 3 (BH3)-only proteins. They can regulate directly and/or indirectly the remaining Bcl-2 proteins to endanger mitochondria and induce apoptosis. We chose three molecules from the BH3-only family, Puma, Noxa and Bim, respectively, which had shown an exciting antitumor potential in previous reports, to explore their characters and functions in tumorigenesis, therapy and drug resistance of CLL.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries. It is a heterogeneous disease characterized by the accumulation of mature CD5 þ CD19 þ CD23 þ B lymphocytes in peripheral blood, bone marrow, lymph nodes and spleen. 1 Although the entire pathogenesis of CLL has not been clarified, it was previously assumed that CLL was associated with a defective regulation of apoptosis, rather than uncontrolled cell proliferation, as the vast majority of tumor cells did not display a high proliferative capacity. 2 Therefore, we paid more attention to the restoration of the apoptotic pathway as a novel approach for treating CLL. It is well known that there are two main pathways of apoptosis: the extrinsic pathway triggered by death signals from cell surface and the intrinsic or B-cell lymphoma 2 (Bcl-2) family-regulated pathway started with the perturbation of mitochondria. Bcl-2 homology 3 (BH3)-only proteins are pro-apoptotic members within the Bcl-2 family that can regulate directly and/or indirectly the remaining anti-and proapoptotic Bcl-2 proteins to endanger mitochondria and induce apoptosis. 3 Here we chose Puma, Noxa and Bim from BH3-only family to explore their characters and functions in CLL.
MEMBERS OF THE BCL-2 FAMILY
Members of the Bcl-2 family are able to regulate cell death in response to a wide range of intracellular stress signals, including hypoxia, growth factor or cytokine deprivation, DNA damage, certain anticancer drugs and so on. 4, 5 This protein family contains three structurally and functionally distinct subgroups characterized by structural motives called BH domains (Table 1) . Anti-apoptotic members share four such homology domains (BH1-4), whereas pro-apoptotic members possess either three BH domains (BH1-3) or only the BH3 domain. [4] [5] [6] [7] Those that carry BH1-3 are considered to be the effectors of pro-apoptotic Bcl-2 proteins, but recently they have also been suggested containing a BH4 domain. 8 Many Bcl-2 proteins also contain a hydrophobic transmembrane domain, which is not necessarily present in each member ( Figure 1 ).
THE MECHANISM OF BH3-ONLY FAMILY REGULATING THE INTRINSIC PATHWAY
When cells receive intrinsic death signals, there will be a transcriptional upregulation and/or activation of pro-apoptotic BH3-only proteins such as Bim, Bid, Bad, Bmf, Noxa and Puma. These proteins are able to bind anti-apoptotic members of the family (for example, Bcl-2, Bcl-X L , Bcl-W and/or Mcl-1) and inhibit their activity. In addition to inhibiting anti-apoptotic proteins, some direct activators (for example, Bid and Bim) also bind and activate the effectors Bak and Bax. Once activated, Bak and Bax can form an oligomer and subsequently punch pores in the outer mitochondrial membrane, leading to mitochondrial outer membrane permeabilization. Afterwards, pro-apoptotic proteins such as cytochrome c and second mitochondria-derived activator caspase (SMAC) are released from the intermembrane space into the cytosol where they initiate a cascade of caspase activation events that result in apoptosis (Figure 2) . activate Bak or Bax. Sensitizer/de-repressor proteins contain Bad, Bmf, Hrk Harakiri, Noxa and Puma. [11] [12] [13] [14] [15] [16] Furthermore, the interaction between certain BH3-only proteins and antiapoptotic Bcl-2 family members is selective. Bid, Bim and Puma are able to bind all the anti-apoptotic Bcl-2 members, whereas Bad, Noxa and Bmf can only bind some specific ones. [12] [13] [14] [15] [16] At present, the exact mechanism(s) by which the BH3-only proteins interact within the Bcl-2 family network remains controversial. It is unlikely that one pro-apoptotic Bcl-2 protein is sufficient to start apoptosis, but the breakage of balance between anti-and proapoptotic factors will decide the cell's fate.
PUMA, NOXA AND BIM ARE THREE IMPORTANT MEMBERS OF THE BH3-ONLY FAMILY Puma (p53 upregulated modulator of apoptosis) Once transcriptionally activated, the Puma gene produces two transcripts: Puma-a and Puma-b, both of which contain the BH3 domain that can interact with other members of the Bcl-2 family. 13 Among all the transcriptional regulators of Puma, p53 is the most famous one. Puma is a critical mediator of p53-dependent and p53-independent apoptosis induced by a wide variety of stimuli, including deregulated oncogene expression, toxins, growth factor/ cytokine withdrawal, infection and so on. 13 For example, in the event of DNA damage, p53 is activated by the ataxia telangiectasia-mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) pathways and then induces the production of Puma as a transcription factor. 17 Puma can also be activated independently of p53 and thus plays an important role in p53-independent apoptosis. The p53 homolog p73 can also regulate Puma expression by binding to the same p53-responsive elements in the Puma promoter. The forkhead family member forkhead box O3A (FoxO3a), C/EBP homologous protein (CHOP) and E2F1 are also involved in Puma upregulation by a p53-independent way. 18 Moreover, general transcription factors, including C/EBPb, CREB, c-Jun and Sp1, have been implicated in Puma induction, some of which may do so by cooperating with p53 or p73. 13 On the other hand, Puma transcription can also be negatively regulated through the p53 pathway, as p53 activates the transcriptional repressor Slug, which in turn inhibits the transcription of Puma.
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Some alternative splice products of p73 (DNp73 and p73a) or p63 (DNp63) and microRNA can cut down the expression of Puma as well. 20 Recently, posttranscriptional regulation of Puma has been reported to be the phosphorylation at multiple sites, which promotes its proteasomal degradation. 21 It is worth noting that Puma seems to be more powerful than p53 as the deletion of Puma can protect against apoptosis, rivaling the degree of protection when p53 is deleted. 22 Puma is believed to bind and/or activate Bax and Bak through Bid and Bim. 6, 10, 13 However, it has been suggested that Puma can also sponsor apoptosis by directly activating Bax, or through cytoplasmic p53 in some cells. 23 Although we cannot identify whether Puma is able to active Bax and Bak directly, there are no signs that the follow-up would change. In addition, Puma also functions through Bax to induce mitochondrial autophagy in response to mitochondrial perturbations, and under some circumstances, the autophagy can enhance apoptosis. 24 Noxa A decade after its initial identification, Noxa was defined as a p53-inducible gene that took part in DNA damage and hypoxiainduced apoptosis. 14, 22 Similar to Puma, more recent work has demonstrated a p53-independent induction of Noxa involving either E2F1 or p73. 25, 26 It is not surprising that Noxa is less effective than Puma in p53-mediated apoptosis, for Puma (like Bim) can bind to all the anti-apoptotic Bcl-2 family members, whereas Noxa antagonizes only Mcl-1 and A1. Nevertheless, the functional overlap of Noxa and Puma in apoptosis caused by DNA damage indicates that, to some extent, they may cooperate in the progress of apoptosis. When the function of Puma is compromised, the level and/or activation state of Noxa is heightened. 27 Noxa has been proven as a particularly relevant therapeutic target for CLL because it interacts specifically with Mcl-1, thus neutralizing its anti-apoptotic activity. 28 It is interesting that the ratio of Noxa/Mcl-1 in peripheral versus lymph node CLL cell is correlated with survival capacity. 29 This fact clearly indicates that the Noxa/Mcl-1 axis is an attractive target for apoptosis-based therapeutic strategies in CLL.
Bim (Bcl-2-interacting mediator of cell death) Three isoforms of Bim exist because of alternative mRNA splicing, which are usually described as short, long and extra-long (BimS, BimL and BimEL, respectively). The pro-apoptotic activity of Bim is regulated by transcriptional as well as posttranscriptional mechanisms. The forkhead-like transcription factor FOXO3a and tumor suppressor gene runt-related protein 3 (Runx3) are key transcriptional regulators of Bim. 30 Bim can be regulated posttranscriptionally through a series of phosphorylation events.
Recently, Bim has been suggested to interact with all the prosurvival members of the Bcl-2 family. Of all BH3-only proteins examined, only Bim and Bid have the capacity to act as direct activators of Bax and Bak. Bim and Puma also have clearly overlapping functions in p53-dependent and p53-independent apoptosis. In vitro, Bim is essential for apoptosis of various cell types, including lymphocytes (especially germinal center-derived memory B cells and antibody-forming cells), mast cells, osteoclasts, epithelial cells, endothelial cells and neurons. 31, 32 THE DELETION OF PUMA, NOXA OR BIM MAY INCREASE THE TUMOR BURDEN BUT DO NOT CONTRIBUTE TO TUMORIGENESIS Several experiments confirmed that Puma deficiency could both increase B-lineage cells and accelerate the development of B lymphoma. Meanwhile, decreased Noxa or Bim expression was also reported in several human malignancies, including B-cell lymphoma, colon cancer and small-cell lung cancer. 33, 34 Naturally, animals lacking these three genes can be logically expected to be tumor prone. However, this is exactly not the case as Puma À / À , Noxa À / À , Bim À / À or even Puma À / À Noxa À / À mice do not spontaneously form tumors. 33, 35, 36 Only in the Em-myc mouse model of B-cell lymphoma, the loss of single Puma or Bim sensitizes the mice to tumorigenesis. 33, 35 In order to clarify whether the three molecules were able to initiate tumorigenesis, we detected the mRNA levels of Puma, Noxa, Bim and Bcl-2 genes in 100 CLL patients and 10 normal controls, and then found that the expression level of Puma was not significantly distinct with normal controls, but the levels of Noxa, Bim and Bcl-2 were overexpressed in CLL cells. 37 Furthermore, we noticed that low Puma expression level was significantly correlated with variant clinical features and biocharacteristics that could intimate a poor prognosis. Together, we hypothesize that the lower expression of Puma, Noxa and/or Bim is related to the high tumor burden (proliferation of lymphocytes) but does not contribute to tumorigenesis. There appeared to be some redundancy in Noxa and Bim regulation of apoptosis, which was overcome by Bcl-2 overexpression. It implies that tumorigenesis is a complex process, and the balance between pro-and anti-apoptotic regulators determines the fate of a cell. When anti-apoptotic Bcl-2 family members are overexpressed, the ratio of pro-and anti-apoptotic Bcl-2 family members is disturbed and apoptosis can be prevented.
TREATMENT TARGETING THE BH3-ONLY REGULATED APOPTOSIS PATHWAY IS A BREAKTHROUGH IN THE ANTI-TUMOR THERAPY OF CLL
Cyclophosphamide. Cyclophosphamide can kill tumor cells by causing DNA damaging, which is thought to occur largely through the activation of the intrinsic apoptosis pathway by the tumor suppressor p53. Puma and Noxa are direct transcriptional targets of p53, and hence they were naturally thought to take part in this mechanism. Unexpectedly, not only Puma and Noxa but also Bim, 38 which was not known to be a direct p53 target, contributed to the progress. These three BH3-only proteins do cooperate in cyclophosphamide-induced lymphoma cell death in vitro and in vivo, and the level of drug resistance observed in these tripleknockout lymphomas was as severe as that seen with the loss of p53.
38 Surprisingly, with the loss of both Puma and Noxa, lymphomas became more sensitive to cyclophosphamide in vitro, which is perhaps because of a rebalance between prosurvival Bcl-2 family members and BH3-only proteins. 39 Fludarabine. Fludarabine is a kind of the purine analog currently applied in CLL patients, and it removes CLL cells by activating p53 and then downstream BH3-only family members, consequent on the induction of DNA damage. However, which one of the BH3-only family members is the key factor in this apoptotic pathway is still unknown. We incubated CLL cells with an active metabolite of fludarabine, 9-b-D-arabinosyl-2-fluoroadenine (F-ara-A), in vitro and then analyzed the role of Puma, Noxa and Bim in p53-mediated apoptosis of CLL cells. 37 We found that only Puma was the essential factor, and Noxa and Bim seemed to play a more restricted role. Moreover, functional p53 was necessary in fludarabine-induced apoptosis. Puma expression was strongly augmented in a p53-dependent manner, and this was more prominent in cells with mutated immunoglobulin heavy-chain variable region (IGHV) genes, which indicated a significantly better overall survival rate than patients with unmutated IGHV genes. Histone deacetylase inhibitors (HDACis). HDACis are a new class of targeted anticancer agents that exert antitumor activity by their ability to induce growth arrest, differentiation and apoptosis. 40, 41 The precise mechanism whereby HDACis induce apoptosis has not been clarified, but most studies suggest that they rely on the intrinsic pathway. 42 Recent studies show that there is a rapid and extensive upregulation of Noxa and Bim caused by HDACis in CLL and other leukemic cells. 43 Moreover, HDACi-mediated upregulation of Noxa is associated with the amount of Mcl-1 immunoprecipitated. 43 It is valuable for us to ponder this phenomenon. Increased Noxa may neutralize Mcl-1 and inactivate the major member of anti-apoptotic Bcl-2 family members. This is significant in tumors such as CLL, where Mcl-1 is proposed to be an important anti-apoptotic protein. 44 The role of Puma, Noxa and Bim in CLL L-N ZHANG et al
The Noxa/Mcl-1 ratio may be a key prognosis factor in CLL patients treated with HDACis. Glucocorticoids. Glucocorticoids are valid inducers of apoptosis in CLL cells, through a caspase-dependent mechanism. However, their mechanism of apoptosis remains unknown. Current studies using microarray approaches demonstrate that Bim mRNA and protein are both upregulated by glucocorticoids in CLL cells. [45] [46] [47] Other reports also offer evidence that the induction of Bim by glucocorticoids is essential for the complete apoptotic response in acute lymphoblastic leukemia cell lines and xenografts. 48, 49 In an opposite manner, Bim À / À T lymphocytes are partially resistant to glucocorticoid-induced apoptosis. 50 The specific mechanism for the induction of Bim by glucocorticoids remains unclear. However, it could be an indirect mechanism, as the human Bim promoter does not contain a clear glucocorticoid response element. 46 Besides, the downregulation of Mcl-1 has also existed when glucocorticoids upregulate the expression of Bim. We suppose that it is because of Bim's combination with Mcl-1, which inhibits the anti-apoptotic activity of Mcl-1. Analogously, the Bim/Mcl-1 ratio may be a prognosis factor in CLL patients treated with glucocorticoids.
BH3-only mimetic molecules are gene-targeted therapies for CLL Several BH3-only mimetic drugs that inhibit anti-apoptotic proteins activity have been developed. These molecules are designed to bind the hydrophobic groove of anti-apoptotic Bcl-2 proteins and oligomerize Bax or Bak, which can subsequently depolarize mitochondrial membrane potential to release cytochrome c. This new approach carries conspicuous advantages, as restraining the anti-apoptotic proteins using BH3 mimetics should be more valid than targeting the upstream signaling steps, which are often defective because of oncogenic alterations. In recent years, these BH3-only mimetic drugs have displayed the greatest success in clinical trials of many kinds of cancers, especially CLL, as Bcl-2 family proteins were confirmed highly expressed in CLL lymphocytes (Table 2) .
Among all these mimetics, ABT-737 and Gossypol are likely to be the most promising ones for CLL therapy. ABT-737 and its oral form, ABT-263, have been reported to have the strongest binding affinities to the anti-apoptotic members Bcl-2, Bcl-X L and Bcl-W. Mechanistic studies reveal that ABT-737 is similar to the BH3 domain of Bad. 70 Importantly, unlike most of the other BH3 mimetics, ABT-737-induced apoptosis is Bak/Bax dependent, as evidenced by the finding that Bak À / À Bax À / À mouse embryonic fibroblasts are resistant to the treatment. 53 ABT-737 exhibits cytotoxicity against a broad panel of lymphoma cell lines, including mantle cell lymphoma, diffuse large B-cell lymphoma and CLL. [51] [52] [53] [54] [55] [56] For most tumor cell lines, especially those derived from solid tumors, the cell-killing activity of ABT-737 is not satisfying as a single agent. 70 However, it exhibits striking synergy when combined with a variety of anticancer agents, including genotoxic agents etoposide, doxorubicin, cisplatin and melphalan, the antimetabolite drug arabinoside, the microtubule-targeting agents paclitaxel and vincristine, the glucocorticoid dexamethasone and the anti-inflammatory agent thalidomide, especially the proteasome inhibitors bortezomib or carfilzomib. 53, 56, 71 ABT-737 plus bortezomib induced significant apoptosis in primary samples of mantle cell lymphoma, diffuse large B-cell lymphoma, and CLL but no significant cytotoxic effect was observed in peripheral blood mononuclear cells from healthy donors. 71 Thus, combination therapy with ABT-737 may lower the doses of conventional anticancer agents required for clinical responses to reduce collateral damage to normal cells, or ensure more stable remissions without lowering doses.
Gossypol is the first compound that shows inhibition of Bcl-2, Bcl-X L and Mcl-1. Gossypol exhibits a type of enantiomerism that arises from restricted rotation: the ( À )gossypol isomer shows greater cytotoxicity than the ( þ )isomer in several human cancer cell lines. 72 Gossypol and its analogs can mainly bind and interact with the anti-apoptotic proteins Bcl-2 and Bcl-X L , and afterwards induce cytochrome c release and Bak activation in whole cells as well as in isolated mitochondria that express high levels of Bcl-2. 73 Further studies show that gossypol also induces Bax/Bakindependent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2. 74 Although this compound has been primarily studied as an inhibitor of Bcl-2, its other mechanisms of action have also been proposed. An extrinsic cell death pathway through upregulation of Fas/Fas ligand could mediate by gossypol as well. It has been reported earlier that gossypol also induced apoptosis in chronic lymphocytic leukemia through the generation of reactive oxygen species that in turn mediate the release of cytochrome c, thus causing apoptosis. 75 It is worth noting that the apoptotic effect of gossypol in CLL cells is not associated with the Rai stage of the disease, prior treatment, ZAP-70 or immunoglobulin status, IGHV mutation, p53 status, chromosomal trisomy or ATM mutation. 75 Hence, patients with poor prognosis will benefit a lot from gossypol. As a single agent or in combination with chemotherapy, gossypol is effective in lymphoma cells.
PUMA, NOXA AND BIM ARE ABLE TO RESTORE THE SENSITIVITY OF CLL CELLS TO CHEMOTHERAPEUTIC AGENTS Drug resistance in CLL contributes to poor clinical outcomes and remains a significant obstacle to successful chemotherapy. At least two mechanisms contribute to the development of resistance to drugs: acquired mutations resulting in a dysfunctional p53 response 76, 77 and shifts in the balance between apoptosisregulating proteins. 78 Strategies to overcome resistance mechanisms are therefore highly needed.
Inactivation of p53 reportedly occurs in 15-25% of CLL patients, which is caused either by p53 mutation 79 or inactivation of the gene encoding ATM, 80 a kinase that regulates p53. Restoration of the p53 pathway by activating p53 itself or p53 downstream Bcl-X L, Mcl-1 AML, CLL Preclinical TW-37 [67] [68] [69] Bcl-X L , Mcl-1, Bcl-2 CLL, non-Hodgkin's lymphoma, head and neck cancer, pancreatic cancer, small-cell lung cancer Preclinical Abbreviations: AML, acute myeloid leukemia; Bcl-2, B-cell lymphoma 2; CLL, chronic lymphocytic leukemia.
The role of Puma, Noxa and Bim in CLL L-N ZHANG et al targets has been explored to improve the efficacy of anticancer therapies. Puma is an essential mediator of p53-dependent and p53-independent apoptosis, 22 and hence it turns into the most promising candidate. Low dose of Ad-Puma was confirmed to restore significantly the sensitivity of cancer cells to chemotherapeutic agents in vitro and in vivo through restoration of the p53 pathway in human melanoma 81 and choriocarcinoma 82 cell lines. Conversely, targeted deletion of Puma in human colorectal cancer cells resulted in resistance to apoptosis induced by p53, the DNA-damaging agent adriamycin and hypoxia. 83 The reason why Puma is able to ameliorate the drug resistance of CLL can be divided into three aspects. At first, Puma could induce apoptosis in malignant cells regardless of p53 status. In addition, Puma can be a more effective radiosensitizer and chemosensitizer for tumors compared with p53 as it is a downstream target of p53. Otherwise, tumors treated with Adp53 often show higher expression of p21 compared with AdPuma. 82 It suggests the possibility that overexpression of p21 may sometimes result in cell cycle arrest, rather than apoptosis, as high level of p21 is known to inhibit apoptosis. However, this possibility needs to be further evaluated in other kinds of cancer cells and in vivo tumor models.
Increased expression levels of Bcl-2 family members, particularly Mcl-1 (MCL-1expression has in vitro and in vivo significance in CLL), have been associated with resistance to chemotherapy. CLL cells originating from lymph nodes show an altered expression of apoptotic genes, high Bcl-X L and Mcl-1 and low Noxa levels 29 compared with CLL cells from peripheral blood, which can result in microenvironment-induced resistance to cytotoxic agents. An approach to overcome this kind of drug resistance could be to alter the cellular apoptotic balance. Hence, we hypothesize that either decreasing Mcl-1 level or increasing Noxa level will result in synergistic effects with chemotherapy for CLL cells in chemoresistant niches. 84 It is confirmed by a recent study that shows that Noxa/Mcl-1 balance determines sensitivity to ABT-737 in CD40-stimulated (mimics the lymph node microenvironment) CLL cells and that increasing the Noxa/Mcl-1 ratio results in synergy with ABT-737. 85 Certainly, the mechanisms of chemoresistance are complicated and interconnected. In many cases, these two mechanisms exist at the same time. Forodesine is a transition state inhibitor of the purine nucleoside phosphorylase. It is highly cytotoxic in primary leukemic cells from CLL patients regardless of p53 or ATM deletion because forodesine induces transcriptional upregulation of p73, a p53-related protein that is able to overcome the resistance to apoptosis of CLL cells lacking functional p53. Simultaneously, forodesine activates the mitochondrial apoptotic pathway by decreasing the level of MCL-1 protein and increasing the level of Bim protein. 86 
CONCLUSIONS AND FUTURE PERSPECTIVES
In summary, the loss or inactivation of Puma, Noxa and Bim might increase the tumor burden but do not contribute to tumorigenesis. Besides, they are able to mediate apoptosis induced by the common chemotherapeutics in CLL and BH3-only mimetics to benefit CLL patients. These three proteins can improve the prognosis of refractory CLL as they seem to have the capability of sensitizing cancer cells to chemotherapeutic agents. However, there are still many conundrums that remain unsolved, like the exact relationship between tumorigenesis and BH3-only proteins and the precisely curative effect of BH3 mimetics.
